Lung; Disease, Interstitial, With Fibrosis
7
2
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Partitioned Training of Patients With Idiopathic Pulmonary Fibrosis
Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
BPF Genetics of ILD Study
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers
Deep Learning Diagnostic and Risk-stratification for IPF and COPD
Basiliximab Treating Interstitial Pneumonia of CADM
Mechanisms of Exertional Dyspnea in Fibrotic Interstitial Lung Disease